Bicavera 4.25 % Glukoosi, 1.25 Mmol/L Kalsium 4,25 % glukoosi, 1,25 mmol/l kalsium peritoneaalidialyysineste Фінляндія - фінська - Fimea (Suomen lääkevirasto)

bicavera 4.25 % glukoosi, 1.25 mmol/l kalsium 4,25 % glukoosi, 1,25 mmol/l kalsium peritoneaalidialyysineste

fresenius medical care deutschland gmbh - calcium chloride dihydrate, magnesium chloride hexahydrate, sodium hydrogen carbonate, glucose monohydrate, sodium chloride - peritoneaalidialyysineste - 4,25 % glukoosi, 1,25 mmol/l kalsium - hypertoniset liuokset

Apixaban Accord Європейський Союз - фінська - EMA (European Medicines Agency)

apixaban accord

accord healthcare s.l.u. - apixaban - venous thromboembolism; stroke; arthroplasty - antitromboottiset aineet - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery. ehkäisy aivohalvauksen ja systeemisen embolian ehkäisyyn aikuispotilailla, joilla on ei-läppäperäinen eteisvärinä (nvaf), jossa on yksi tai useampia riskitekijöitä, kuten ennen aivohalvaus tai ohimenevä aivoverenkiertohäiriö (tia); ikä ≥ 75 vuotta; kohonnut verenpaine; diabetes mellitus; oireinen sydämen vajaatoiminta (nyha-luokka ≥ ii). hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla (ks. kohta 4. 4 hemodynaamisesti epävakaa pe potilaat). prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii). hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla (ks. kohta 4. 4 hemodynaamisesti epävakaa pe potilaat).

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Європейський Союз - фінська - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroksabaani - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitromboottiset aineet - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Mycapssa Європейський Союз - фінська - EMA (European Medicines Agency)

mycapssa

amryt pharmaceuticals dac - octreotide acetate - akromegalia - aivolisäkkeen ja hypotalamuksen hormonit ja analogit - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Crestor 10 mg tabletti, kalvopäällysteinen Фінляндія - фінська - Fimea (Suomen lääkevirasto)

crestor 10 mg tabletti, kalvopäällysteinen

astrazeneca oy - rosuvastatin calcium - tabletti, kalvopäällysteinen - 10 mg - rosuvastatiini

Crestor 20 mg tabletti, kalvopäällysteinen Фінляндія - фінська - Fimea (Suomen lääkevirasto)

crestor 20 mg tabletti, kalvopäällysteinen

astrazeneca oy - rosuvastatin calcium - tabletti, kalvopäällysteinen - 20 mg - rosuvastatiini

Crestor 40 mg tabletti, kalvopäällysteinen Фінляндія - фінська - Fimea (Suomen lääkevirasto)

crestor 40 mg tabletti, kalvopäällysteinen

astrazeneca oy - rosuvastatin calcium - tabletti, kalvopäällysteinen - 40 mg - rosuvastatiini

Crestor 5 mg tabletti, kalvopäällysteinen Фінляндія - фінська - Fimea (Suomen lääkevirasto)

crestor 5 mg tabletti, kalvopäällysteinen

astrazeneca oy - rosuvastatin calcium - tabletti, kalvopäällysteinen - 5 mg - rosuvastatiini

ALVESCO 40 mikrog/annos inhalaatiosumute, liuos Фінляндія - фінська - Fimea (Suomen lääkevirasto)

alvesco 40 mikrog/annos inhalaatiosumute, liuos

takeda gmbh - ciclesonidum - inhalaatiosumute, liuos - 40 mikrog/annos - siklesonidi

ROSUVASTATIN ACTAVIS 5 mg tabletti, kalvopäällysteinen Фінляндія - фінська - Fimea (Suomen lääkevirasto)

rosuvastatin actavis 5 mg tabletti, kalvopäällysteinen

actavis group ptc ehf - rosuvastatinum calcicum - tabletti, kalvopäällysteinen - 5 mg - rosuvastatiini